Lyra Therapeutics, Inc. LYRA · Stock Open Lyra Therapeutics, Inc. in new tab
Lyra Therapeutics, Inc. Analysis (LYRA)
Is Lyra Therapeutics, Inc. a good investment? Lyra Therapeutics, Inc. (LYRA) is currently trading at 0.2000 USD.
Earnings Schedule: Lyra Therapeutics, Inc. is expected to release its next earnings report on Nov. 17, 2026. The market consensus estimate for Forward EPS is -0.99.
Investor FAQ
Does Lyra Therapeutics, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Lyra Therapeutics, Inc.?
Lyra Therapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 17, 2026. The company currently has a trailing EPS of -18.62.
Company Profile
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
| Split Date | Split Ratio to 1 |
|---|---|
| May 28, 2025 | 1:50 |
Community Discussion